Abstract
The importance of Akt, Erk, and their downstream effectors-mediated signaling is indisputable for the proliferation of cell. Growth factor-induced activation of Akt and Erk pathways interacts with each other to regulate proliferation. However, an instructive model, wiring the crucial signaling nodes working in cellular growth and division, is still absent or controversial. Although growth factor-mediated mTORC1 regulation is defined considerably, debates still exist formTORC2. TSC1-TSC2 complex integrates both nutrient and mitogenic signals coming from growth factor receptors. Growth factor-induced PI3K/Akt- and Ras/Erk-mediated TSC2 inhibition is well defined. However, the interaction between TSC complex and new molecules such as Pin1 and DAPK requires further clarifications. Furthermore, the Wnt-β-catenin signaling pathway also intersects with the growth factor signaling at TSC1/TSC2 junction. Therefore, the aim of this perspective paper is to suggest an integrated model, linking growth factor-activated crucial signaling nodes in order to supply key molecular connections to degenerative diseases.
Keywords: Akt, β-catenin, Erk, E2F1, DAPK, GSK3, mTORC1, mTORC2, Pin1, Wnt
Current Molecular Medicine
Title:An Integrated and Disease-Oriented Growth Factor-Regulated Signal Transduction Network
Volume: 13 Issue: 1
Author(s): A. Erol
Affiliation:
Keywords: Akt, β-catenin, Erk, E2F1, DAPK, GSK3, mTORC1, mTORC2, Pin1, Wnt
Abstract: The importance of Akt, Erk, and their downstream effectors-mediated signaling is indisputable for the proliferation of cell. Growth factor-induced activation of Akt and Erk pathways interacts with each other to regulate proliferation. However, an instructive model, wiring the crucial signaling nodes working in cellular growth and division, is still absent or controversial. Although growth factor-mediated mTORC1 regulation is defined considerably, debates still exist formTORC2. TSC1-TSC2 complex integrates both nutrient and mitogenic signals coming from growth factor receptors. Growth factor-induced PI3K/Akt- and Ras/Erk-mediated TSC2 inhibition is well defined. However, the interaction between TSC complex and new molecules such as Pin1 and DAPK requires further clarifications. Furthermore, the Wnt-β-catenin signaling pathway also intersects with the growth factor signaling at TSC1/TSC2 junction. Therefore, the aim of this perspective paper is to suggest an integrated model, linking growth factor-activated crucial signaling nodes in order to supply key molecular connections to degenerative diseases.
Export Options
About this article
Cite this article as:
Erol A., An Integrated and Disease-Oriented Growth Factor-Regulated Signal Transduction Network, Current Molecular Medicine 2013; 13 (1) . https://dx.doi.org/10.2174/1566524011307010086
DOI https://dx.doi.org/10.2174/1566524011307010086 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Oligonucleotide-based Gene Therapy for Cardiovascular Disease Are Oligonucleotide Therapeutics Novel Cardiovascular Drugs
Current Drug Targets Sumoylation in Cellular Senescence and Aging
Current Molecular Medicine Molecular Pathogenesis of Philadelphia-Positive Chronic Myeloid Leukemia – is it all BCR-ABL?
Current Cancer Drug Targets Chalcones Incorporated Pyrazole Ring Inhibit Proliferation, Cell Cycle Progression, Angiogenesis and Induce Apoptosis of MCF7 Cell Line
Anti-Cancer Agents in Medicinal Chemistry Plant Glycosides and Aglycones Displaying Antiproliferative and Antitumour Activities – A Review
Current Bioactive Compounds PEDF as an Emerging Therapeutic Candidate for Osteosarcoma
Current Cancer Drug Targets Interactions of Vascular Endothelial Growth Factor and p53 with miR-195 in Thyroid Carcinoma: Possible Therapeutic Targets in Aggressive Thyroid Cancers
Current Cancer Drug Targets The Current and Future Therapies for Human Osteosarcoma
Current Cancer Therapy Reviews Stress Hormone-Mediated DNA Damage Response -- Implications for Cellular Senescence and Tumour Progression
Current Drug Targets mTOR: A Novel Therapeutic Target for Diseases of Multiple Systems
Current Drug Targets Selective Cytotoxic Effects of 5-Trifluoromethoxy-<i>1H</i>-indole-2,3-dione 3-Thiosemicarbazone Derivatives on Lymphoid-originated Cells
Anti-Cancer Agents in Medicinal Chemistry Role of Nuclear Steroid Receptors in Apoptosis
Current Medicinal Chemistry Targeted Therapies in Lung Cancers: Current Landscape and Future Prospects
Recent Patents on Anti-Cancer Drug Discovery Analysis of Codon Usage Patterns in the Human Papillomavirus Oncogenes
Current Bioinformatics Recent Advances in Therapeutic Peptides for Breast Cancer Treatment
Current Protein & Peptide Science Cell Penetrating Peptides for Tumor Targeting
Current Pharmaceutical Biotechnology Preferentially Expressed Antigen in Melanoma (PRAME) and the PRAME Family of Leucine-Rich Repeat Proteins
Current Cancer Drug Targets FGF10 and FGF21 as Regulators in Adipocyte Development and Metabolism
Endocrine, Metabolic & Immune Disorders - Drug Targets Cardiac Gene Therapy: Therapeutic Potential and Current Progress
Current Gene Therapy Immunotherapeutic Options for Pediatric Malignancies
Current Immunology Reviews (Discontinued)